New Delhi, June 24
Danish pharmaceutical company Novo Nordisk on Tuesday launched its once-weekly injectable weight-loss drug Wegovy in India, at Rs 4,336.25 per dose.
Wegovy, a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA), is the first and only weight management medication in India.
The drug, with semaglutide as the active ingredient, is indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events in people living with the condition.
The drug is available in five dosing -- 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg -- and comes with the convenience of an innovative, easy-to-use pen device.
The first three will be priced at 4,336 rupees, and the monthly price for the drug starts at Rs 17,345 per pen, the company said.
On the other hand, 1.7 mg is priced at Rs 24,280 per pen, and 2.4 mg is priced at Rs 26,015 per pen.
Wegovy is a prescription-only medication that has the potential to improve the quality of life for millions of Indians living with obesity or overweight, the company said.